Pro Medicus share price soars on rocketing revenues, profits, dividends

Are Pro Medicus Limited (ASX: PME) shares a buy?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This morning medical imaging software business Pro Medicus Limited (ASX: PME) reported a net profit of $19.1 million on revenue of $50.1 million for the financial year ending June 30, 2019. The profit and revenue are up 92% and 48% respectively over the prior fiscal year. When adjusting for currency gains and new accounting standards net profit came in at $22.7 million, up 83%.

Using the adjusted net profit of $22.7 million we can see that this software-as-a-service business is operating on sky high net profit margins of 45.3%, which you'll be hard pushed to find anywhere else on the S&P/ ASX200 (ASX: XJO).

The company will pay a final dividend of 4.5 cents per share to take total dividends to 10.5 cents per share including special dividends. But, it won't impress your parents with a 0.3% yield based on a $29 share price. 

Diluted earnings per share came in at 18.32 cents to mean the stock trades on 158x FY 2019's earnings or 59x sales based on 103.4 million shares on issue and a $29 share price to give a market value of $2.998 billion.

This kind of valuation has caused value investors to label the stock a 'bubble' recently. However, it's the attractive economics, recurring revenues, scalability and strong outlook of this business that means investors prize it so highly. 

For example today it flagged it has $180 million of contracted revenue locked in already over the next 5 years with a full sales pipeline and multiple other opportunities to grow revenue from existing and new customers. It also has the opportunity to lift its already sky high profit margins. 

Finally it should be noted that high profit margins are the calling card of a high-quality or market-leading tech and healthcare business that has 'pricing power' as another investment characteristic. 

When you add in a strong balance sheet with $32 million cash in hand and a founder running the business for more than 25 years you can see why it's highly valued.

A conventional 158x PE may seem ridiculous, but if it can keep doubling profits that falls to 40x in FY 2021 for a business already profitable, paying dividends, and positioned to keep growing.

A compound doubling of profits out to FY 2021 may be too bullish, but is useful as an example in helping understand the market's valuation. 

Others I'd suggest investors take a close look at include Altium Limited (ASX: ALU) and Xero Limited (ASX: XRO).

Tom Richardson owns shares of Altium, Pro Medicus Ltd., and Xero.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Xero. The Motley Fool Australia owns shares of Altium. The Motley Fool Australia has recommended Pro Medicus Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Best Shares

Top ASX shares to buy with $500 in November 2024

$500 worth of ASX shares might not sound like a huge investment. But, to realise the benefits of compounding, you…

Read more »

A diverse group of people form a circle at a park and raise their arms together.
Share Market News

Here are the top 10 ASX 200 shares today

ASX investors ended the trading week on a high note this Friday...

Read more »

Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Catapult, De Grey Mining, Domino's, and Nufarm shares are charging higher

These shares are ending the week strongly. But why?

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Three analysts look at tech options on a wall screen
Technology Shares

Up 70%, is it too late to invest in Xero shares?

This ASX tech darling hit a new all-time share price record yesterday.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why Healius, Opthea, Peninsula Energy, and Wildcat shares are falling today

These shares are having a tough finish to the week. But why?

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Share Market News

Why this ASX uranium share is plunging 25% on Friday

Let's see why investors are smashing the sell button today.

Read more »